低分子肝素治疗急性冠脉综合征的疗效及对外周血血细胞膜表面组织因子的影响
|
摘要
目的:探讨低分子肝素治疗急性冠脉综合征(ACS)的临床疗效以及对外周血血细胞膜表面组织因子的影响。方法:选取2015年1月至2016年9月承德医学院附属医院收治的80例ACS患者,按照随机数字表法将其分为观察组和对照组,每组40例。对照组采用常规治疗,观察组在对照组基础上采用低分子肝素钙治疗。比较两组临床疗效,观察治疗前、后外周血血细胞膜表面组织因子的表达及不良反应发生情况。结果:观察组治疗的总有效率为95.0%,明显高于对照组的77.5%,差异有统计学意义(P<0.05);与对照组相比,观察组治疗后外周血血细胞膜表面组织因子表达量明显降低,差异有统计学意义(P<0.05)。治疗期间两组患者均无严重不良反应发生。结论:低分子肝素治疗ACS具有较好的临床疗效及安全性,并且能抑制外周血血细胞膜表面组织因子的表达。
Objective:To study the clinical efficacy of low molecular weight heparin(LMWH)in the treatment of acute coronary syndrome(ACS)and its impact on the surface tissue factor of peripheral blood.Methods:80 ACS patients in our hospital from Jan 2015 to Sep 2016 were randomized into a control group(routine treatment)and an observation group(low molecular weight heparin),with 40 cases per group.The clinical efficacy,the expression of surface tissue factor of peripheral blood cell pre-and post-treatment,and the adverse reactions during the treatment between the two groups were compared.Results:Compared to the control group,the total effective rate was significantly increased in the observation group(P<0.05),and the expression of peripheral blood cell surface tissue factor was obviously reduced at post-treatment in the observation group(P<0.05).No severe adverse reactions were noted in both groups.Conclusion:LMWH was effective and safe in the treatment of ACS,and it could inhibit the expression of the surface tissue factor of peripheral blood cell.
Objective:To study the clinical efficacy of low molecular weight heparin(LMWH)in the treatment of acute coronary syndrome(ACS)and its impact on the surface tissue factor of peripheral blood.Methods:80 ACS patients in our hospital from Jan 2015 to Sep 2016 were randomized into a control group(routine treatment)and an observation group(low molecular weight heparin),with 40 cases per group.The clinical efficacy,the expression of surface tissue factor of peripheral blood cell pre-and post-treatment,and the adverse reactions during the treatment between the two groups were compared.Results:Compared to the control group,the total effective rate was significantly increased in the observation group(P<0.05),and the expression of peripheral blood cell surface tissue factor was obviously reduced at post-treatment in the observation group(P<0.05).No severe adverse reactions were noted in both groups.Conclusion:LMWH was effective and safe in the treatment of ACS,and it could inhibit the expression of the surface tissue factor of peripheral blood cell.
引文
[1]BRUNETTI N D,MUNNO I,PELLEGRINO P L,et al.Inflammatory cytokines imbalance in the very early phase of acute coronary syndrome:correlations with angiographic findings and in-hospital events[J].Inflammation,2011,34:58-66.
[2]陈国伟,顾菊康,陈濒珠.心血管病诊断治疗学[M].合肥:安徽科学技术出版社,2013:272-273.
[3]薛仁洪.低分子肝素治疗急性冠脉综合征的临床分析[J].深圳中西医结合杂志,2015,25(4):155-156.
[4]贾旭荣,黎红,韦诚,等.低分子肝素与肝素治疗急性冠脉综合征的疗效与安全性[J].中国生化药物杂志,2011,32(3):230-232.
[5]黄细莲,钱申贤,刘利蓉,等.2型糖尿病患者外周血血细胞膜表面组织因子的表达及活性的研究[J].中国老年学杂志,2009,29(24):3249-3251.
[6]王吉耀.内科学[M].北京:人民卫生出版社,2005:266-289.
[7]龙世平.肝素与低分子肝素治疗急性冠脉综合征的疗效和安全性[J].中国医药导刊,2012,14(7):1212-1213.
[8]冯姗,罗雪勇,王军贤.通心络胶囊联合低分子肝素治疗急性冠脉综合征[J].中国实验方剂学杂志,2013,19(10):340-342.
[9]MURAKAMI M,LWASAKI K,KUSACHI S,et al.Nieorandil reduces the incidence of minor cardiac marker elevation after coronary stenting[J].Int J Cardiol,2014,107(1):48-53.
[10]杜晓马,蔡建丽,沈昕.脑心通胶囊联合低分子肝素钙对急性冠脉综合征患者血清hs-CRP、IL-6及血脂的影响[J].中国现代医生,2014,52(17):8-11.
[11]彭晓燕.低分子肝素联合脑心通对急性冠脉综合征患者机体炎症反应及血管内皮功能的影响[J].中国当代医药,2015,22(36):65-68.
[12]曹维彬,罗海燕,郝晓红,等.外周血血细胞膜表面组织因子在急性冠脉综合征患者中的表达及活性研究[J].中华血液学杂志,2013,34(3):264-266.
[13]ABERG M,ERIKSSON O,SIEGBAHN A.Tissue factor noncoagulant signaling:mechanisms and implications for cell migration and apoptosis[J].Semin Thromb Hemost,2015,41(7):691-699.
[14]黄细莲,陈况,谢亚萍,等.冠心病患者外周血血细胞膜表面组织因子的表达与活性的研究[J].心脑血管病防治,2011,11(2):112-114.
[15]郭钦惠,袁劲松.低分子肝素治疗急性冠脉综合征对于外周血血细胞膜表面组织因子的影响分析[J].中国医药科学,2014,4(6):56-58.
[2]陈国伟,顾菊康,陈濒珠.心血管病诊断治疗学[M].合肥:安徽科学技术出版社,2013:272-273.
[3]薛仁洪.低分子肝素治疗急性冠脉综合征的临床分析[J].深圳中西医结合杂志,2015,25(4):155-156.
[4]贾旭荣,黎红,韦诚,等.低分子肝素与肝素治疗急性冠脉综合征的疗效与安全性[J].中国生化药物杂志,2011,32(3):230-232.
[5]黄细莲,钱申贤,刘利蓉,等.2型糖尿病患者外周血血细胞膜表面组织因子的表达及活性的研究[J].中国老年学杂志,2009,29(24):3249-3251.
[6]王吉耀.内科学[M].北京:人民卫生出版社,2005:266-289.
[7]龙世平.肝素与低分子肝素治疗急性冠脉综合征的疗效和安全性[J].中国医药导刊,2012,14(7):1212-1213.
[8]冯姗,罗雪勇,王军贤.通心络胶囊联合低分子肝素治疗急性冠脉综合征[J].中国实验方剂学杂志,2013,19(10):340-342.
[9]MURAKAMI M,LWASAKI K,KUSACHI S,et al.Nieorandil reduces the incidence of minor cardiac marker elevation after coronary stenting[J].Int J Cardiol,2014,107(1):48-53.
[10]杜晓马,蔡建丽,沈昕.脑心通胶囊联合低分子肝素钙对急性冠脉综合征患者血清hs-CRP、IL-6及血脂的影响[J].中国现代医生,2014,52(17):8-11.
[11]彭晓燕.低分子肝素联合脑心通对急性冠脉综合征患者机体炎症反应及血管内皮功能的影响[J].中国当代医药,2015,22(36):65-68.
[12]曹维彬,罗海燕,郝晓红,等.外周血血细胞膜表面组织因子在急性冠脉综合征患者中的表达及活性研究[J].中华血液学杂志,2013,34(3):264-266.
[13]ABERG M,ERIKSSON O,SIEGBAHN A.Tissue factor noncoagulant signaling:mechanisms and implications for cell migration and apoptosis[J].Semin Thromb Hemost,2015,41(7):691-699.
[14]黄细莲,陈况,谢亚萍,等.冠心病患者外周血血细胞膜表面组织因子的表达与活性的研究[J].心脑血管病防治,2011,11(2):112-114.
[15]郭钦惠,袁劲松.低分子肝素治疗急性冠脉综合征对于外周血血细胞膜表面组织因子的影响分析[J].中国医药科学,2014,4(6):56-58.